trial

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

NCTId NCT01328093
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 678 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2012-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
678 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-04
Primary completion
2012-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadAripiprazole

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

51 total
Cerritos, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesOakland, United StatesSherman Oaks, United StatesCoral Gables, United StatesMaitland, United StatesNorth Miami, United StatesSanford, United StatesChicago, United StatesIndianapolis, United States

Linked catalysts

1
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients — primary completion2012-10

Facts & assertions

4 sourced
Enrollment
678
Phase
PHASE3
Primary Completion Date
2012-10
Status
TERMINATED
relationships
The graph out of here
drug
Pomaglumetad
drug
Aripiprazole
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person